CNTA Key Statistics, Chart & Performance
The current stock price of CNTA is 25.73 USD. In the past month the price increased by 0.19%. In the past year, price increased by 52.07%.
CNTA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 86.74% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. CNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.57. The EPS decreased by -2.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.14% | ||
| ROE | -80.48% | ||
| Debt/Equity | 0.36 |
CNTA Forecast & Estimates
21 analysts have analysed CNTA and the average price target is 39.78 USD. This implies a price increase of 54.61% is expected in the next year compared to the current price of 25.73.
CNTA Ownership
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 114 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Company Info
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 114
Phone: 447391789784
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
What does CENTESSA PHARMACEUTICALS-ADR do?
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 114 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
What is the stock price of CENTESSA PHARMACEUTICALS-ADR today?
The current stock price of CNTA is 25.73 USD. The price increased by 1.82% in the last trading session.
What is the dividend status of CENTESSA PHARMACEUTICALS-ADR?
CNTA does not pay a dividend.
How is the ChartMill rating for CENTESSA PHARMACEUTICALS-ADR?
CNTA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for CENTESSA PHARMACEUTICALS-ADR?
CENTESSA PHARMACEUTICALS-ADR (CNTA) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for CENTESSA PHARMACEUTICALS-ADR?
CENTESSA PHARMACEUTICALS-ADR (CNTA) currently has 114 employees.
When does CENTESSA PHARMACEUTICALS-ADR (CNTA) report earnings?
CENTESSA PHARMACEUTICALS-ADR (CNTA) will report earnings on 2026-03-23, after the market close.